Literature DB >> 17044021

Broad tumor spectrum in a mouse model of multiple endocrine neoplasia type 1.

Kelly A Loffler1, Christine A Biondi, Michael Gartside, Paul Waring, Mitchell Stark, Magdalena M Serewko-Auret, H Konrad Muller, Nicholas K Hayward, Graham F Kay.   

Abstract

Multiple endocrine neoplasia type 1 (MEN1) is an inherited cancer predisposition syndrome typified by development of tumors in parathyroid, pituitary and endocrine pancreas, as well as less common sites including both endocrine and nonendocrine organs. Deletion or mutation of the tumor suppressor gene MEN1 on chromosome 11 has been identified in many cases of MEN1 as well as in sporadic tumors. The molecular biology of menin, the protein encoded by MEN1, remains poorly understood. Here we describe a mouse model of MEN1 in which tumors were seen in pancreatic islets, pituitary, thyroid and parathyroid, adrenal glands, testes and ovaries. The observed tumor spectrum therefore includes types commonly seen in MEN1 patients and additional types. Pancreatic pathology was most common, evident in over 80% of animals, while other tumor types developed with lower frequency and generally later onset. Tumors of multiple endocrine organs were observed frequently, but progression to carcinoma and metastasis were not evident. Tumors in all sites showed loss of heterozygosity at the Men1 locus, though the frequency in testicular tumors was only 36%, indicating that a different molecular mechanism of tumorigenesis occurs in those Leydig tumors that do not show loss of the normal Men1 allele. Menin expression was below the level of detection in ovary, thyroid and testis, but loss of nuclear menin immunoreactivity was observed uniformly in all pancreatic islet adenomas and in some hyperplastic islet cells, suggesting that complete loss of Men1 is a critical point in islet tumor progression in this model. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17044021     DOI: 10.1002/ijc.22288

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  33 in total

1.  Pathogenesis of gastrinomas associated with multiple endocrine neoplasia type 1.

Authors:  D M Pritchard
Journal:  Gut       Date:  2007-05       Impact factor: 23.059

Review 2.  Review paper: origin and molecular pathology of adrenocortical neoplasms.

Authors:  M Bielinska; H Parviainen; S Kiiveri; M Heikinheimo; D B Wilson
Journal:  Vet Pathol       Date:  2009-03       Impact factor: 2.221

Review 3.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 4.  The mammalian ovary from genesis to revelation.

Authors:  Mark A Edson; Ankur K Nagaraja; Martin M Matzuk
Journal:  Endocr Rev       Date:  2009-09-23       Impact factor: 19.871

5.  Exploring the tumors of multiple endocrine neoplasia type 1 in mouse models for basic and preclinical studies.

Authors:  Sunita K Agarwal
Journal:  Int J Endocr Oncol       Date:  2014

Review 6.  Mouse models of endocrine tumours.

Authors:  Georgette N Jones; Parmeet K Manchanda; Daphne R Pringle; Mei Zhang; Lawrence S Kirschner
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-06       Impact factor: 4.690

7.  Recapitulation of pancreatic neuroendocrine tumors in human multiple endocrine neoplasia type I syndrome via Pdx1-directed inactivation of Men1.

Authors:  H-C Jennifer Shen; Mei He; Anathea Powell; Asha Adem; Dominique Lorang; Charles Heller; Amelia C Grover; Kris Ylaya; Stephen M Hewitt; Stephen J Marx; Allen M Spiegel; Steven K Libutti
Journal:  Cancer Res       Date:  2009-02-10       Impact factor: 12.701

8.  Conditional deletion of p53 and Rb in the renin-expressing compartment of the pancreas leads to a highly penetrant metastatic pancreatic neuroendocrine carcinoma.

Authors:  S T Glenn; C A Jones; S Sexton; C M LeVea; S M Caraker; G Hajduczok; K W Gross
Journal:  Oncogene       Date:  2013-12-02       Impact factor: 9.867

Review 9.  The future: genetics advances in MEN1 therapeutic approaches and management strategies.

Authors:  Sunita K Agarwal
Journal:  Endocr Relat Cancer       Date:  2017-10       Impact factor: 5.678

10.  Parathyroid tumor development involves deregulation of homeobox genes.

Authors:  H-C Jennifer Shen; Jennifer E Rosen; Lauren M Yang; Sharon A Savage; A Lee Burns; Carmen M Mateo; Sunita K Agarwal; Settara C Chandrasekharappa; Allen M Spiegel; Francis S Collins; Stephen J Marx; Steven K Libutti
Journal:  Endocr Relat Cancer       Date:  2008-03       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.